Monocentric retrospective study to assess factors associated with lipid variations in HIV1-infected patients after switching to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide
Latest Information Update: 29 May 2019
At a glance
- Drugs Cobicistat/elvitegravir/emtricitabine/tenofovir alafenamide (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions
Most Recent Events
- 29 May 2019 New trial record
- 16 Apr 2019 Results presented at the 29th European Congress of Clinical Microbiology and Infectious Diseases